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in Human Primary Leukemia 
By Koichi Miyake, Koiti Inokuchi, Kazuo Dan, and Takeo Nomura 
To evaluate the role of the deleted in colorectal carcinoma 
(DCC)  gene  in  leukemogenesis, we examined  loss  of 
heterozygosity (LOH) in the DCC gene in 64  primary hu- 
man leukemias using Southern blot analysis  and examined 
the expression of the DCC gene using reverse transcrip- 
tase-polymerase chain reaction (RT-PCR) analysis. Allelic 
loss in the DCC gene was observed in two patients (6%. 2 
of 35 informative cases), and expression of the DCC gene 
was reduced or  absent in 8 of  26 (31%)  patients with 
ECENT STUDIES on the molecular mechanisms of  R  oncogenesis have  shown  a  multiple-step  process,'X2 
such as activation of oncogenes and inactivation of tumor- 
suppressor genes. In leukemogenesis, a mutated N-ras gene 
is detected in about 20% -30%  of acute myelogenous leu- 
kemia  (AML)   patient^,^  whereas  a  bcr-ab1  fusion  gene 
formed by a reciprocal translocation between chromosomes 
9 and 22 is detected in more than 90% of chronic myeloge- 
nous leukemia (CML) and about 20% of acute lymphoid 
leukemia (ALL)  patient^.^ Recently, some reports showed 
inactivation of tumor-suppressor genes in human leukemia. 
Alterations of the p53 gene have been reported in AML,'p6 
and in blast crisis of CML patients.I0l3 Deletion of 
the retinoblastoma (Rb) gene have been reported in some 
human leukemias.14-'*  These reports suggest that in addi- 
tion to activation of some oncogenes, alterations of some 
tumor-suppressor genes contribute to leukemogenesis. 
The deleted in colorectal carcinomas (DCC)  gene, located 
in human chromosome band 18q2  1, was identified as a po- 
tential tumor-suppressor gene by Fearon et al in 1990.19 In 
colorectal carcinoma, allelic deletion  in the DCC gene is 
detected in about 7 1 % of cases, and it shows reduced expres- 
sion in  88% of cases."  More recently, Tanaka et alZ0  re- 
ported that introduction of a single normal human chromo- 
some 18 into a human colon carcinoma cell line suppressed 
its tumorigenicity. And Narayanan et aIz1  showed direct bio- 
logic evidence for the possible role of DCC as a tumor-sup- 
pressor gene using an antisense RNA technique. These find- 
ings suggest that the DCC gene might be a tumor-suppressor 
gene. Here, to evaluate the role of the DCC gene in leuke- 
mogenesis, we analyzed the loss of heterozygosity (LOH) in 
the DCC gene in 64 primary human leukemia cases using 
Southern blot analysis and examined expression ofthe DCC 
gene using the reverse transcriptase-polymerase chain reac- 
tion (RT-PCR) method. 
MATERIALS  AND  METHODS 
Primary human  leukemia cells were  obtained 
from bone marrow (BM) aspirates or peripheral blood (PB) from 64 
patients at the time of diagnosis, after obtaining informed consent. 
The patients consisted of 26 patients with AML, 9 with ALL, and 
29 with CML (of which 23 were  in chronic phase and 6 in blast 
crisis). Thirty-five patients with acute leukemia were classified ac- 
cording to the French-American-British (FAB) criteria as follows: 
one patient with  MO  AML?'  six with  MI AML, eight with  M2 
AML, three with M3 AML, six with M4 AML, one with M5 AML, 
one with M6 AML, three with LI ALL, five with L2 ALL, and one 
Cell samples. 
acute myelogenous  leukemia (AML), 3 of 9 (33%)  patients 
with acute lymphocytic leukemia (ALL), and 7 of 29 (24%) 
patients with chronic myelogenous  leukemia (CML). More- 
over, in one ALL patient with absent DCC expression at 
diagnosis, its expression became normal after performing 
chemotherapy and  achieving  remission. These  findings 
suggest that inactivation of the DCC gene contributes to 
some instances of leukemogenesis. 
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with  L3 ALL.  The diagnosis and classifications of the 29 CML 
patients were based on standard clinical, morphologic, cytochemi- 
cal and immunologic criteria. The Philadelphia chromosome was 
detected in  all  of  the patients. As  normal control samples, BM 
mononuclear cells in  the remission stage, skin biopsy, and gastric 
biopsy were obtained from the same patients after obtaining in- 
formed consent. 
Southern blot analysis.  Cell isolation and DNA extraction were 
performed as previously de~cribed.'~  After the genomic DNA was 
digested to completion with appropriate restriction endonucleases 
(EcoRI or MspI; Boehringer Mannheim, Germany), 10  pg of di- 
gested DNA was size-fractionated by 0.8% standard agarose  gel elec- 
trophoresis and transferred onto nylon membrane filters (Gene 
Screen Plus; New  England Nuclear, Boston, MA) in  IO X  SSC 
(standard saline citrate) overnight. Hybridization was performed 
according to the protocol provided by  New  England Nuclear, as 
described previou~ly.'~  The filters were hybridized with "P-labeled 
probes at 63°C and visualized on autoradiograms. The following 
probes  and  restriction  enzymes  were  used  in  this  study: 
pDCC1.65" (EcoRI);  p15-6519  (Mspl);  and SAM I. 125 (EcoRI). For 
internal control of sample DNA quality, same filters  were rehybrid- 
ized with '*P-labeled N-ras probe, which was a Hind111 fragment 
containing exon  1 of N-ras gene.24 
RT-PCR  for detection ofDCCmRNA.  The total RNA ofmono- 
nuclear cells was extracted by  the CsCl method.z6  The integrity of 
the RNA samples  was determined by formaldehyde-agarose  gel elec- 
trophoresis, and degraded RNA samples were rejected. RT-PCR 
was performed as described previou~ly.~~  First, cDNA synthesis was 
performed using an oligonucleotide primer (DCC2: 5'-AGCCTC- 
ATTTTCAGCCACACA-3', antisense strand). PCR  was performed 
with 10 pL of cDNA reaction mixture by using 0.0125 OD26o  (opti- 
cal density) units of each oligonucleotide  primer (DCCI: 5'-TTC- 
CGCCATGGTTTTTAAATCA-3',  coding strand; and DCC2: anti- 
sense strand). These oligonucleotide  primers are the Same ones as 
used by  Fearon et allg The reaction conditions and cycle number 
were as previously described.27  Twenty microliters  ofthe PCR prod- 
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ucts were phenol-extracted. ethanol-precipitated, electrophoresed 
through a 4% agarose gel (NuSciene 3: I  Agarose: FMC BioProd- 
ucts, Rockland, ME), and transferred onto nylon membrane filters. 
Hybridization  was  performed  with  the  ”P-labeled  pDCCl.65 
probe. To show the intactness  ofthe RNA, we examined the expres- 
sion ofD-actin mRNA as a control using an oligonucleotide primer 
(actin  I:  5’-AACGGCTCCGGCATGTGCAA-3’. coding  strand: 
and  actin  2:  5’-CTTCTGACCCATGCCCACCA-3’.  antisense 
strand)**  by the same RT-PCR assay. 
RESULTS 
We examined 64 DNA samples 
from the primary human leukemia cases by Southern blot 
using the pDCCl.65 cDNA probe. We found no definitive 
rearrangements in the DCC gene. However, we found loss 
of 20-kb and/or 14-kb EcoRI fragments (Fig IAa) in two 
patients.  This  probe  detects  two  diallelic  polymorphic 
EcoRI sites on Southern blot (20-kb and 14-kb EcoRI frag- 
ments), as Kikuchi-Yanoshita et a129 reported.  To expect 
that two bands (20- and 14-kb) would be involved in allelic 
loss,  we  showed  allelic loss  using standard polymorphic 
probes from the DCC locus (pl5-65 and SAM 1.1) in two 
patients. In this study, pl5-65 detected an MspI polymor- 
phism with two alleles of  10.5 and 7.8  kb,I9 and SAM1.l 
detected  an EcoRI polymorphism with two alleles of 9.2 
and 1.1 kb.25  One case was a 29-year-old female AML(M 1) 
patient  with  98.2% blasts  in  her  BM  at diagnosis.  We 
showed LOH using pl5-65 probe. Two alleles were present 
in the normal DNA (skin biopsy), but only the 7.8-kb allele 
was present in the DNA from leukemic cells (Fig 1Ab). But 
unfortunately, SAM 1.1 was ‘not informative.’ The second 
case was a 57-year-old male ALL patient with 88% blasts in 
his BM at diagnosis. The karyotype of all his blast cells had 
an abnormality of  I8q-.  After performing chemotherapy, 
he achieved remission. Compared with the remission sam- 
Soutliern blot analjais. 
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ple, the DNA of his blast cells showed homozygous loss by 
SAM I. 1  and p 15-65 (Fig  1 Ba, b).  To show that approxi- 
mately equal amounts of DNA were placed in the lanes, we 
rehybridized these membranes with N-ras probe. In addi- 
tion, although we performed Southern blot analysis for five 
patients with CML in both the chronic phase and blast cri- 
sis, we could not find any abnormalities in the DCC gene in 
any of the samples (data not shown). 
RT-PCR  analysis.  Twenty-two  normal  samples were 
obtained from BM aspirates from healthy volunteers after 
obtaining  informed  consent, and they were examined  as 
normal controls. We examined expression of the DCC gene 
by  the RT-PCR  method in 64 human primary  leukemia 
samples and 22 normal human samples. Whereas we found 
no abnormal (reduced or absent) expression of the DCC 
gene in any of the normal control samples, which showed a 
233-bp fragment, expression of the DCC gene was absent or 
extremely reduced in 8 of the 26 AML samples (31%), 3 of 
the 9 ALL samples (33%), and 7 of the 29 CML samples 
(24%)  (Fig 2A). These data are summarized in Table I. We 
also examined a remission sample of one ALL (L2) patient. 
She was an 18-year-old girl with 89.2% blasts in her BM. 
Whereas expression of the DCC gene was absent at diagno- 
sis, its expression was detected after performing chemother- 
apy and achieving remission (Fig 2B). Moreover, we exam- 
ined the expression ofthe DCC gene in five CML patients in 
both the chronic phase and blast crisis. Four of the 5 pa- 
tients showed normal DCC expression in both the chronic 
phase and blastic crisis, and the fifth patient lacked DCC 
gene expression in both phases (data not shown). 
DISCUSSION 
The DCC gene encodes a protein that is highly similar to 
neural cell adhesion molecules and other related cell-surface 
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Fig 1 .  Examples of Southern 
blot analysis of the DCC gene in 
primary  human leukemia. Ten 
micrograms  of  genomic  DNA 
digested  with  EcoRl  or  Mspl, 
was  electrophoresed on 0.8% 
agarose gel and transferred  to a 
nylon  membrane.  The  mem- 
brane  was  hybridized  to  a 
pDCC1.65  or  p15-65  or 
SAM1.l  probe.  (A) DNA from 
skin biopsy (lane 1) and leuke- 
mic cells (lane 2) in an AML pa- 
tient. (a): pDCCl.65, €coRI di- 
gest. (b): pl5-65, Mspl digest. 
(B) DNA from BM  mononuclear 
cells of remission sample (lane 
1)  and leukemic cells (lane 2) in 
an  ALL  patient.  (a): SAM1.l, 
EcoRl digest. (b): pl5-65,  Mspl 
digest.  To show that approxi- 
mately equal amounts of DNA 
were placed in the lanes, 9.2- 
kb EcoRl digested  and  5.5-kb 
Mspl  digested  N-ras  exon  1 
fragments are  shown at bot- 
tom. 
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glycoproteins (GPs). Disruption of cell adhesion molecules 
(CAMs) might play  a role in tumorigenesis.  Neoplasia  is 
often associated with disruption of such cell-cell contacts, 
and intercellular  adhesion mediated by  CAMs influences 
cellular differentiati~n.~’  Our findings of reduced or absent 
expression of the DCC gene in some leukemia patients sug- 
gest that the DCC gene plays a role in leukemogenesis. 
We detected allelic loss in the DCC gene in two patients. 
One patient showed hemizygous loss and the other showed 
homozygous loss. We think that homozygous loss is very 
uncommon evidence. We think that in the two patients who 
showed allelic loss,  it was pure chance that one patient 
showed homozygous loss. We detected  reduced or absent 
DCC expression in  18 of 64 (28%) leukemia patients.  We 
detected allelic loss in the DCC gene in two of the patients 
with reduced or absent DCC expression, and no abnormal- 
ity ofthe DCC gene could be detected in another 16 patients 
in Southern blot analysis. Thus, we speculate that a point 
mutation or an insertion in the DCC gene and alteration in 
an initiator or promoter area in the DCC gene may contrib- 
ute to reduced or absent DCC expression as well as allelic 
loss (LOH) in the DCC gene. Further study is needed to 
elucidate the possible mechanisms. 
The molecular mechanisms of the progression from the 
chronic phase to the blastic phase in CML are still unclear. 
Some reports have suggested that blastic transformation of 
CML might be associated with tumor-suppressor genes such 
as the p53  or Rb gene.”  We examined  DCC ex- 
pression in six CML blast crisis samples. Its expression was 
extremely reduced in only one sample. Moreover, we exam- 
ined the expression ofthe  DCC gene in five CML patients in 
both the chronic phase and blastic crisis. Four of the 5  pa- 
tients  had  normal  DCC expression  in  both the chronic 
phase and blastic crisis, and the fifth patient lacked DCC 
gene expression in both phases (data not shown). Thus, the 
DCC gene might be involved in the early stage of CML, but 
not in blastic transformation. 
A 
bp  12345678 
233 n  0 
108 moooooooo  0  m  p -actin 
Fig 2.  Expression of the DCC gene by RT-PCR analysis in hu- 
man leukemia patients. After cDNA was produced using a DCC2 
primer, PCR was performed using DCCl and DCC2 primers. The 
PCR products were size-fractionated by 4.0%  agarose gel electro- 
phoresis, transferred to a  nylon membrane,  and hybridized to a 
pDCCl.65 probe. Expression of the &actin gene is shown in the 
lower panel by the same RT-PCR assay as a control. (A) Lanes 1 
and 2 are control samples from BM  mononuclear cells from healthy 
humans. Lanes 3 to 9 are leukemic cell samples from AML (lanes 3 
and 7). ALL (lanes 4 and 8). and CML (lanes 5, 6, and 9) patients. 
Expression  of the DCC gene was absent in lanes 3 to 5 and lane 9, 
and remarkably reduced in lanes 6 and 8. (B) Lane 1 is a control 
sample. Lane 2 is from an ALL patient at diagnosis, and lane 3 is 
from the same patient in the remission stage.  Expression of the 
DCC gene was remarkably reduced in lane 2 but present in lane 3. 
Table 1.  Expression of DCC Gene in Primary Human Leukemia 
No. of  No. of Patients 
Patients  With Reduced or  Frequency 
Diagnosis  Examined  Absent Expression  (%I 
AML  26  8  31 
MO  1  1 
M1  6  2 
M2  8  3 
M3  3  1 
M4  5  1 
M5  1  0 
M6  1  0 
ALL  9  3 
L1  3  1 
L2  6  2 
L3  1  0 
Chronic phase  23  6 
Blast crisis  6  1 
Normal sample’  22  0 
CML  29  7  24 
Total  64  18  28 
* EM samples from healthy volunteers were examined. 
33 
In conclusion, we detected allelic loss in the DCC gene in 
two patients (6%, 2 of  35  informative cases) and absent or 
reduced expression of the DCC gene in 18 of 64 (28%) pri- 
mary  human  leukemia  cases.  Although  the  full-length 
cDNA of the DCC gene and the function of the DCC pro- 
tein remain unknown, our data strongly suggest that inacti- 
vation  of the DCC gene is involved in some instances of 
leukemogenesis. 
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